These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 25531357

  • 1. Biosimilars: are they bioequivalent?
    Gomollón F.
    Dig Dis; 2014; 32 Suppl 1():82-7. PubMed ID: 25531357
    [Abstract] [Full Text] [Related]

  • 2. Biosimilars in inflammatory bowel disease: ready for prime time?
    Gomollón F.
    Curr Opin Gastroenterol; 2015 Jul; 31(4):290-5. PubMed ID: 26039720
    [Abstract] [Full Text] [Related]

  • 3. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S, Heap GA, Ahmad T, Kim H, Kwon T, Chowers Y.
    Expert Rev Gastroenterol Hepatol; 2015 Jul; 9 Suppl 1():27-34. PubMed ID: 26395532
    [Abstract] [Full Text] [Related]

  • 4. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S, Luger T, Mittendorf T, Mrowietz U, Müller-Ladner U, Schröder J, Stallmach A, Bokemeyer B.
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [Abstract] [Full Text] [Related]

  • 5. Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.
    Annese V, Vecchi M, Italian Group for the Study of IBD (IG-IBD).
    Dig Liver Dis; 2014 Nov; 46(11):963-8. PubMed ID: 25139379
    [Abstract] [Full Text] [Related]

  • 6. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
    Reinisch W, Louis E, Danese S.
    Expert Rev Gastroenterol Hepatol; 2015 Nov; 9 Suppl 1():17-26. PubMed ID: 26395531
    [Abstract] [Full Text] [Related]

  • 7. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
    Schellekens H, Lietzan E, Faccin F, Venema J.
    Expert Opin Biol Ther; 2015 Nov; 15(11):1633-46. PubMed ID: 26365396
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inflammatory diseases: Integrating biosimilars into clinical practice.
    Feldman SR.
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical trial development for biosimilars.
    Alten R, Cronstein BN.
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550
    [Abstract] [Full Text] [Related]

  • 12. A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.
    Ha CY, Kornbluth A.
    Inflamm Bowel Dis; 2016 Oct; 22(10):2513-26. PubMed ID: 27564646
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists.
    Teixeira FV, Kotze PG, Damião AO, Miszputen SJ.
    Arq Gastroenterol; 2015 Oct; 52(1):76-80. PubMed ID: 26017088
    [Abstract] [Full Text] [Related]

  • 15. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G, Gilardi D, Correale C, Furfaro F, Roda G, Loy L, Argollo M, Allocca M, Peyrin-Biroulet L, Danese S.
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [Abstract] [Full Text] [Related]

  • 16. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
    Taylor P.
    Expert Rev Clin Immunol; 2015 Oct; 11 Suppl 1():S1-4. PubMed ID: 26395831
    [Abstract] [Full Text] [Related]

  • 17. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P, Fiorino G, Danese S.
    Curr Pharm Des; 2017 Oct; 23(44):6759-6769. PubMed ID: 29205114
    [Abstract] [Full Text] [Related]

  • 18. Biosimilars in inflammatory bowel disease.
    Gargallo CJ, Lué A, Gomollón F.
    Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
    [Abstract] [Full Text] [Related]

  • 19. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T, Letkovsky J.
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [Abstract] [Full Text] [Related]

  • 20. Biosimilars in Dermatology: Current Situation (Part II).
    Puig L, Carretero G, Daudén E, Ferrándiz C, Marrón SE, Martorell A, Pérez-Suárez B, Rodriguez-Cerdeira C, Ruiz-Villaverde R, Sánchez-Carazo JL, Velasco M, en nombre del Grupo de Psoriasis de Academia Española de Dermatología y Venereología.
    Actas Dermosifiliogr; 2015 Sep; 106(7):550-4. PubMed ID: 26049964
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.